Abstract:To evaluate the effect of treatment with beta-conglycinin, a major soyabean protein, on blood lipids in menopausal women, we recruited 100 hyperlipidaemic women aged 40-60 years old. Participants were randomly allocated to three groups: placebo group (n 34, four casein tablets/d); low dose group (n 33, four tablets containing 2.3 g b-conglycinin/d); high-dose group (n 33, eight tablets containing 4.6 g beta-conglycinin/d). The mean serum TAG concentration was significantly reduced after 6 and 12 weeks of beta-conglycinin intervention by 0.44 (SD 0.20) and 0.78 (SD 1.03) mmol/l in the low-dose group, and by 0.46 (SD 0.17) and 1.25 (SD 1.06) mmol/l in the high-dose group, respectively. One-way ANOVA revealed that serum TAG concentrations in the low-dose and high-dose groups were significantly lowered compared with the placebo group at weeks 6 and 12 (P, 0.05). The low dose and high dose consumptions of b-conglycinin significantly decreased the LDL-cholesterol concentration by 0.46 (SD 0.72) and 0.52 (SD 0.97) mmol/l at week 12, respectively (P, 0.05). Compared with the changes from baseline in the placebo group, apoB and NEFA were significantly lowered in both the low-dose and high-dose b-conglycinin groups (P, 0.05). In conclusion, the results suggest that beta-conglycinin intake significantly decreases serum TAG and LDL-cholesterol levels.

Serum lipid-improving effect of soyabean β-conglycinin in hyperlipidaemic menopausal women.